Poolbeg Pharma gets FDA support for POLB 001 drug Biopharmaceutical company Poolbeg Pharma said the US Food and Drug Administration has granted Orphan Drug Designation (ODD) to its POLB 001 product as an oral preventative therapy for Cytokine Release Syndrome (CRS). Business • 27 May
Poolbeg Pharma gets FDA support for POLB 001 drug Biopharmaceutical company Poolbeg Pharma said the US Food and Drug Administration has granted Orphan Drug Designation (ODD) to its POLB 001 product as an oral preventative therapy for Cytokine Release Syndrome (CRS). Business • 27 May
Poolbeg Pharma used AI to identify RSV drug targets Poolbeg Pharma says it has successfully used artificial intelligence to identify drug targets for the treatment of Respiratory Syncytial Virus (RSV). Business • 20 Dec 23
Poolbeg Pharma used AI to identify RSV drug targets Poolbeg Pharma says it has successfully used artificial intelligence to identify drug targets for the treatment of Respiratory Syncytial Virus (RSV). Business • 20 Dec 23
Open Orphan's Poolbeg Pharma to list on London's AIM Pharmaceutical firm Open Orphan has today announced plans to spin out a Dublin-headquartered company focused on infectious diseases, called Poolbeg Pharma. Business • 17 Jun 21
Open Orphan's Poolbeg Pharma to list on London's AIM Pharmaceutical firm Open Orphan has today announced plans to spin out a Dublin-headquartered company focused on infectious diseases, called Poolbeg Pharma. Business • 17 Jun 21
